Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05297909 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Ascending doses in healthy volunteers |
| Part 2: CSF PKPD | EXPERIMENTAL | Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment |
| Name | Type | Description |
|---|---|---|
| PF-05297909 25 mg | DRUG | Single oral (PO) dose, PF-05297909 25 mg |
| PF-05297909 100 mg | DRUG | Single oral (PO) dose, PF-05297909 100 mg |
| PF-05297909 250 mg | DRUG | Single oral (PO) dose, PF-05297909 250 mg |
| PF-05297909 525 mg | DRUG | Single oral (PO) dose, PF-05297909 525 mg |
Inclusion Criteria: * For Healthy adult volunteers: healthy male and/or female subjects of non child bearing potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, inc...
PF-05297909 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
PF-05297909 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound.
PF-05297909 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed.
PF-05297909 has been evaluated in one completed Phase 1 trial, NCT01462851. The study observed safety and concentrations of PF-05297909 and proteins in blood and cerebrospinal fluid after a single dose in 51 healthy adults in the United States.